Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 13/2016

28.07.2016 | Original Article

The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers

verfasst von: Ivayla Apostolova, Kilian Ego, Ingo G. Steffen, Ralph Buchert, Heinz Wertzel, H. Jost Achenbach, Sandra Riedel, Jens Schreiber, Meinald Schultz, Christian Furth, Thorsten Derlin, Holger Amthauer, Frank Hofheinz, Thomas Kalinski

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Asphericity (ASP) is a tumour shape descriptor based on the PET image. It quantitates the deviation from spherical of the shape of the metabolic tumour volume (MTV). In order to identify its biological correlates, we investigated the relationship between ASP and clinically relevant histopathological and molecular signatures in non-small-cell lung cancer (NSCLC).

Methods

The study included 83 consecutive patients (18 women, aged 66.4 ± 8.9 years) with newly diagnosed NSCLC in whom PET/CT with 18F-FDG had been performed prior to therapy. Primary tumour resection specimens and core biopsies were used for basic histopathology and determination of the Ki-67 proliferation index. EGFR status, VEGF, p53 and ALK expression were obtained in a subgroup of 44 patients. The FDG PET images of the primary tumours were delineated using an automatic algorithm based on adaptive thresholding taking into account local background. In addition to ASP, SUVmax, MTV and some further descriptors of shape and intratumour heterogeneity were assessed as semiquantitative PET measures.

Results

SUVmax, MTV and ASP were associated with pathological T stage (Kruskal-Wallis, p = 0.001, p < 0.0005 and p < 0.0005, respectively) and N stage (p = 0.017, p = 0.003 and p = 0.002, respectively). Only ASP was associated with M stage (p = 0.026). SUVmax, MTV and ASP were correlated with Ki-67 index (Spearman’s rho = 0.326/p = 0.003, rho = 0.302/p = 0.006 and rho = 0.271/p = 0.015, respectively). The latter correlations were considerably stronger in adenocarcinomas than in squamous cell carcinomas. ASP, but not SUVmax or MTV, showed a tendency for a significant association with the extent of VEGF expression (p = 0.058). In multivariate Cox regression analysis, ASP (p < 0.0005) and the presence of distant metastases (p = 0.023) were significantly associated with progression-free survival. ASP (p = 0.006), the presence of distant metastases (p = 0.010), and Ki-67 index (p = 0.062) were significantly associated with overall survival.

Conclusion

The ASP of primary NSCLCs on FDG PET images is associated with tumour dimensions and molecular markers of proliferation and angiogenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.CrossRefPubMed Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.CrossRefPubMed
3.
Zurück zum Zitat Roy S, Pathy S, Kumar R, Mohanti BK, Raina V, Jaiswal A, et al. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung. Nucl Med Commun. 2016;37:129–38. doi:10.1097/MNM.0000000000000422.CrossRefPubMed Roy S, Pathy S, Kumar R, Mohanti BK, Raina V, Jaiswal A, et al. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung. Nucl Med Commun. 2016;37:129–38. doi:10.​1097/​MNM.​0000000000000422​.CrossRefPubMed
4.
Zurück zum Zitat Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26. doi:10.2967/jnumed.112.107375.CrossRefPubMed Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26. doi:10.​2967/​jnumed.​112.​107375.CrossRefPubMed
7.
Zurück zum Zitat Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78. doi:10.2967/jnumed.110.082404.CrossRefPubMedPubMedCentral Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78. doi:10.​2967/​jnumed.​110.​082404.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.1038/ncomms5006.PubMedPubMedCentral Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.​1038/​ncomms5006.PubMedPubMedCentral
10.
Zurück zum Zitat Apostolova I, Steffen IG, Wedel F, Lougovski A, Marnitz S, Derlin T, et al. Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol. 2014;24:2077–87. doi:10.1007/s00330-014-3269-8.CrossRefPubMed Apostolova I, Steffen IG, Wedel F, Lougovski A, Marnitz S, Derlin T, et al. Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol. 2014;24:2077–87. doi:10.​1007/​s00330-014-3269-8.CrossRefPubMed
11.
Zurück zum Zitat Hofheinz F, Lougovski A, Zophel K, Hentschel M, Steffen IG, Apostolova I, et al. Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42:429–37. doi:10.1007/s00259-014-2953-x.CrossRefPubMed Hofheinz F, Lougovski A, Zophel K, Hentschel M, Steffen IG, Apostolova I, et al. Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42:429–37. doi:10.​1007/​s00259-014-2953-x.CrossRefPubMed
15.
Zurück zum Zitat Herbst RS, Bunn Jr PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003;9:5813–24.PubMed Herbst RS, Bunn Jr PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003;9:5813–24.PubMed
17.
Zurück zum Zitat Hofheinz F, Potzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin. 2012;51:9–16. doi:10.3413/Nukmed-0419-11-07.CrossRefPubMed Hofheinz F, Potzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin. 2012;51:9–16. doi:10.​3413/​Nukmed-0419-11-07.CrossRefPubMed
18.
Zurück zum Zitat Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40:082503. doi:10.1118/1.4812892.CrossRefPubMed Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40:082503. doi:10.​1118/​1.​4812892.CrossRefPubMed
19.
Zurück zum Zitat Barber CB, Dobkin DP, Huhdanpaa H. The Quickhull algorithm for convex hulls. ACM Trans Math Softw. 1996;22:469–83.CrossRef Barber CB, Dobkin DP, Huhdanpaa H. The Quickhull algorithm for convex hulls. ACM Trans Math Softw. 1996;22:469–83.CrossRef
20.
Zurück zum Zitat Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44. doi:10.2967/jnumed.114.144055.CrossRefPubMed Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44. doi:10.​2967/​jnumed.​114.​144055.CrossRefPubMed
21.
22.
Zurück zum Zitat van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–47.CrossRefPubMedPubMedCentral van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–47.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Shin Y, Han S, Chung E, Chung S. Intratumoral phenotypic heterogeneity as an encourager of cancer invasion. Integr Biol (Camb). 2014;6:654–61.CrossRef Shin Y, Han S, Chung E, Chung S. Intratumoral phenotypic heterogeneity as an encourager of cancer invasion. Integr Biol (Camb). 2014;6:654–61.CrossRef
24.
Zurück zum Zitat Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853–60. doi:10.1097/PAS.0b013e31821a0696.CrossRefPubMed Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853–60. doi:10.​1097/​PAS.​0b013e31821a0696​.CrossRefPubMed
25.
Zurück zum Zitat Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682–91. doi:10.1007/s00259-015-3110-x.CrossRefPubMed Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682–91. doi:10.​1007/​s00259-015-3110-x.CrossRefPubMed
26.
Zurück zum Zitat Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, et al. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 2014;9:1485–93. doi:10.1097/JTO.0000000000000286.CrossRefPubMed Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, et al. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 2014;9:1485–93. doi:10.​1097/​JTO.​0000000000000286​.CrossRefPubMed
27.
Zurück zum Zitat Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:2058–65. doi:10.1007/s00259-014-2833-4.CrossRefPubMed Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:2058–65. doi:10.​1007/​s00259-014-2833-4.CrossRefPubMed
28.
Zurück zum Zitat Del Gobbo A, Pellegrinelli A, Gaudioso G, Castellani M, Zito Marino F, Franco R, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology. 2016;68:746–51. doi:10.1111/his.12808.CrossRefPubMed Del Gobbo A, Pellegrinelli A, Gaudioso G, Castellani M, Zito Marino F, Franco R, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology. 2016;68:746–51. doi:10.​1111/​his.​12808.CrossRefPubMed
29.
Zurück zum Zitat Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014;55:1235–41. doi:10.2967/jnumed.113.133389.CrossRefPubMed Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014;55:1235–41. doi:10.​2967/​jnumed.​113.​133389.CrossRefPubMed
35.
Zurück zum Zitat Kaida H, Kawahara A, Hayakawa M, Hattori S, Kurata S, Fujimoto K, et al. The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers. Nucl Med Commun. 2014;35:36–43. doi:10.1097/MNM.0000000000000019.CrossRefPubMed Kaida H, Kawahara A, Hayakawa M, Hattori S, Kurata S, Fujimoto K, et al. The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers. Nucl Med Commun. 2014;35:36–43. doi:10.​1097/​MNM.​0000000000000019​.CrossRefPubMed
36.
39.
Zurück zum Zitat De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, et al. Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:5110–20. doi:10.1158/1078-0432.CCR-15-0375.CrossRefPubMed De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, et al. Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:5110–20. doi:10.​1158/​1078-0432.​CCR-15-0375.CrossRefPubMed
Metadaten
Titel
The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers
verfasst von
Ivayla Apostolova
Kilian Ego
Ingo G. Steffen
Ralph Buchert
Heinz Wertzel
H. Jost Achenbach
Sandra Riedel
Jens Schreiber
Meinald Schultz
Christian Furth
Thorsten Derlin
Holger Amthauer
Frank Hofheinz
Thomas Kalinski
Publikationsdatum
28.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3452-z

Weitere Artikel der Ausgabe 13/2016

European Journal of Nuclear Medicine and Molecular Imaging 13/2016 Zur Ausgabe